VSTM2B as A Potent Drug Target for Cancer (G284395)

Target Name: VSTM2B-DT

NCBI ID: G284395

VSTM2B-DT

Other Name(s): VSTM2B divergent transcript

VSTM2B as A Potent Drug Target for Cancer

VSTM2B-DT, or VSTM2B divergent transcript, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. The VSTM2B gene is located on chromosome 6 and encodes for a protein known as VSTM2B, which is a key regulator of microRNA (miRNA) expression.

The VSTM2B protein plays a crucial role in the regulation of gene expression and has been implicated in the development and progression of various diseases, including cancer. Several studies have identified VSTM2B as a potential drug target and have shown that inhibiting its activity can lead to therapeutic effects in animal models of cancer.

One of the key reasons for the potential of VSTM2B as a drug target is its involvement in the regulation of miRNA expression. MiRNA is a type of non-coding RNA molecule whose function is to regulate gene expression. By binding to miRNA molecules, VSTM2B can inhibit their activity, thereby affecting intracellular gene expression. In various cancers, abnormal regulation of miRNA expression is an important cause of tumor occurrence and progression. Therefore, by inhibiting the activity of VSTM2B, miRNA expression levels can be reduced, thereby inhibiting the growth and spread of tumor cells.

In addition, VSTM2B is also related to the cell cycle. It plays a key role in the S phase and G2 phase of the mitosis cycle and can affect the stability of chromosome structure and function. Therefore, inhibition of VSTM2B may affect the structure and function of chromosomes, leading to cell cycle abnormalities, apoptosis and other adverse reactions.

In addition, VSTM2B is also related to the immunogenicity of cells. In tumor cells, VSTM2B can inhibit the killing effect of immune cells on tumor cells, thereby helping tumor cells evade immune surveillance and attack. Therefore, inhibition of VSTM2B may enhance the immunogenicity of tumor cells, making them easier to be recognized and eliminated by the immune system.

In summary, VSTM2B-DT is a drug target with great potential. By inhibiting the activity of VSTM2B, miRNA expression can be inhibited, thereby inhibiting the growth and spread of tumor cells, and enhancing the immunogenicity of tumor cells, making them easier to be recognized and eliminated by the immune system.

Protein Name: VSTM2B Divergent Transcript

The "VSTM2B-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VSTM2B-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets